difference between retatrutide and tirzepatide Weight Loss Blog – Maryland Trim Clinic Tirzepatide vs Retatrutide | Philly

Backed by the ESSENCE Trial - 63% achieved MASH resolution without worsening fibrosis - 37%showed fibrosis improvement without worsening MASH - No increase in cardiovascular risk - Subcutaneous semaglutide 2.4 mg, once weekly Why It Matters

PMID: Summary Keywords GIP/GLP-1 receptor agonist, glucagon-like peptide 1 receptor agonist, glucocorticosteroids, semaglutide, steroid-induced diabetes, steroid-induced hyperglycaemia Citation Jdrasek A, Lisowska K and Czupryniak L (2026) Evaluation of GLP-1 receptor agonist therapy in the management of steroid-induced diabetes: a narrative review

Smart carbs and healthy fats last

Taking other medications as needed

A summary of clinically-significant GLP-1RAs described in this text and their clinical uses are listed in Table 1

Dulaglutide and tirzepatide yielded even less benefit (2.3% loss and 2.3% gain, respectively), suggesting that concurrent endocrine therapy may attenuate the weight loss efficacy of GLP-1 RAs in this population